AMPA antagonists: do they hold more promise for clinical stroke trials than NMDA antagonists?
The cytoprotective effects of MK-801 and NBQX, selective N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor antagonists, respectively, were compared both singularly and in combination in models of transient severe forebrain and transient focal c...
Váldodahkkit: | Buchan, A, Lesiuk, H, Barnes, K, Li, H, Huang, Z, Smith, K, Xue, D |
---|---|
Materiálatiipa: | Journal article |
Giella: | English |
Almmustuhtton: |
1993
|
Geahča maid
-
Delayed treatment with AMPA, but not NMDA, antagonists reduces neocortical infarction.
Dahkki: Xue, D, et al.
Almmustuhtton: (1994) -
DELAYED TREATMENT WITH AMPA BUT NOT NMDA GLUTAMATE ANTAGONISTS REDUCES NEOCORTICAL INFARCTION
Dahkki: Xue, D, et al.
Almmustuhtton: (1992) -
POSTISCHEMIC TREATMENT WITH AMPA, BUT NOT NMDA, ANTAGONISTS PREVENTS CA1 NEURONAL INJURY
Dahkki: Li, H, et al.
Almmustuhtton: (1992) -
The rise and fall of NMDA antagonists for ischemic stroke.
Dahkki: Hoyte, L, et al.
Almmustuhtton: (2004) -
NMDA antagonists: their role in neuroprotection.
Dahkki: Small, D, et al.
Almmustuhtton: (1997)